Navigation Links
Pharmaceutical Water Markets, the Economic Crunch Creates New Opportunities in Southern and Eastern Europe
Date:12/8/2008

LONDON, Dec. 8 /PRNewswire/ -- High Purity Water is a critical ingredient in the manufacturing process of life saving drugs. The continuing demand for high quality water (HQW) is the single biggest driver for the growth of the water treatment systems market segment in the pharmaceutical sector. Frost & Sullivan's European Environment Research Analyst, Karthikeyan Ravikumar, foresees "that the water and wastewater management market in the European pharmaceutical industry has exciting opportunities to offer particularly in the water treatment segment with the overall market experiencing high growth rates".

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

With Europe as the second largest pharmaceutical manufacturing markets around it has emerged as a very lucrative high value opportunity to stake holders in the water industry. Some of the leading players have made significant investments on research and development as well as positioning themselves as providers of specialist solutions for the pharmaceutical sectors. These investments are channelled to enhance innovative water and wastewater treatment solutions, test and improve existing technologies to meet the current and expected changes to the European Pharmacopoeia's water standards.

The European pharmaceutical market is expected to showcase an annual growth rate of around 8-10 percent in the coming years and this is expected to reflect in a steady increase in the need for effective and efficient water as well as wastewater treatment technologies and services.

Furthermore, the current economic situation may open new and interesting opportunities in Southern and Eastern Europe. Karthikeyan Ravikumar reports that "with the economic slowdown triggered from the United States of America spreading to other regions of the globe, the pharmaceutical industries in Europe may take a cautious stand of wait and watch policy". This cautious stand could have an impact on the water and wastewater management needs of pharmaceutical industries. In this period of economic crunch, pharmaceutical companies have indicated an increased interest in moving South and East of Europe, to tap into relatively low production and operational costs.

Frost & Sullivan is in the process of completing a Snapshot Study on Water & Wastewater Treatment in the European Pharmaceutical Industry. In the meantime, if you are interested in receiving more information on the European Water & Wastewater Treatment Markets, please send an e-mail to Chiara Carella - Corporate Communications at chiara.carella@frost.com with your full name, company name, title, telephone number, e-mail address, city and country. Upon receipt of the above information, an overview will be sent to you by e-mail.

All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

    Contacts:
    Chiara Carella
    Corporate Communications - Europe
    P: +44 (0) 20 7343 8314
    E: chiara.carella@frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. ISTA Pharmaceuticals to Participate at the RBC Capital Markets Healthcare Conference
2. Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas
3. Memory Pharmaceuticals Receives NASDAQ Decisions
4. MAP Pharmaceuticals to Present at the 2008 RBC Capital Markets Healthcare Conference
5. Best Practice Database Adds Research Highlighting Effective Tactics of Sales Force and Manufacturing Groups in the Pharmaceutical Industry
6. The Westaim Corporation requisitions meeting of shareholders of NUCRYST Pharmaceuticals to return capital to NUCRYST shareholders
7. Quark Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference
8. Transcept Pharmaceuticals to Participate on Drug Delivery Investor Panel
9. China West II Files Suit Against Genesis Pharmaceuticals and Capital Research Group Inc, Announces Conference Call Details
10. Watson Pharmaceuticals Receives FDA Final Approval for Generic Wellbutrin XL(R) 150 mg
11. Idenix Pharmaceuticals to Present at the PiperJaffray 20th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. ... magazine’s Code Talker Award, an essay contest in which patients and their families pay ... be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
(Date:6/24/2016)... ... , ... Venture Construction Group (VCG) sponsors Luke’s Wings ... the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event ... that have been wounded in battle and their families. Venture Construction Group is a ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... CAMBRIDGE, Mass. , June 24, 2016 /PRNewswire/ ... the Spaulding Rehabilitation Network,s Dean Center for ... of Physical Medicine and Rehabilitation, MIT Hacking Medicine, ... Center for Innovation, today announced the five finalists ... Hackathon for Lyme disease.  More than 100 scientists, ...
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
Breaking Medicine Technology: